Regeneron Pharmaceuticals (REGN) Other Working Capital Changes (2017 - 2026)

Regeneron Pharmaceuticals has reported Other Working Capital Changes for 18 years, with the latest figure at $319.1 million in Q2 2026.

• On a quarterly basis, Other Working Capital Changes rose 38.32% year-over-year to $319.1 million in Q2 2026; TTM through Jun 2026 was $482.8 million, a 126.14% increase from a year earlier, with the FY2025 full-year figure at $375.3 million, down 7.9% from the prior year.
• Other Working Capital Changes was $319.1 million for Q2 2026 at Regeneron Pharmaceuticals, up from $198.6 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $116.9 million in Q1 2024, with the low at -$142.9 million in Q2 2025.
• Average Other Working Capital Changes over 5 years is $21.7 million, with a median of $30.4 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes tumbled 778.61% in 2023, then jumped 15379.41% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$18.7 million in 2022, then slumped by 778.61% to -$164.3 million in 2023, then surged by 133.66% to $55.3 million in 2024, then plunged by 249.73% to -$82.8 million in 2025, then jumped by 485.39% to $319.1 million in 2026.
• The last three Other Working Capital Changes figures came in at $319.1 million (Q2 2026), $198.6 million (Q1 2026), and -$82.8 million (Q4 2025), per Business Quant data.